JP2025505738A - がんの治療 - Google Patents

がんの治療 Download PDF

Info

Publication number
JP2025505738A
JP2025505738A JP2024547619A JP2024547619A JP2025505738A JP 2025505738 A JP2025505738 A JP 2025505738A JP 2024547619 A JP2024547619 A JP 2024547619A JP 2024547619 A JP2024547619 A JP 2024547619A JP 2025505738 A JP2025505738 A JP 2025505738A
Authority
JP
Japan
Prior art keywords
lag
protein
derivative
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505738A5 (enExample
Inventor
トリーベル，フレデリック
Original Assignee
イムテップ エス．アー．エス．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2201803.0A external-priority patent/GB202201803D0/en
Priority claimed from GBGB2218181.2A external-priority patent/GB202218181D0/en
Application filed by イムテップ エス．アー．エス． filed Critical イムテップ エス．アー．エス．
Publication of JP2025505738A publication Critical patent/JP2025505738A/ja
Publication of JP2025505738A5 publication Critical patent/JP2025505738A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024547619A 2022-02-11 2023-02-10 がんの治療 Pending JP2025505738A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2201803.0A GB202201803D0 (en) 2022-02-11 2022-02-11 Treatment of Cancer
GB2201803.0 2022-02-11
GB2218181.2 2022-12-02
GBGB2218181.2A GB202218181D0 (en) 2022-12-02 2022-12-02 Treatment of cancer
PCT/EP2023/053381 WO2023152335A1 (en) 2022-02-11 2023-02-10 Treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025505738A true JP2025505738A (ja) 2025-02-28
JP2025505738A5 JP2025505738A5 (enExample) 2026-02-19

Family

ID=85227021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547619A Pending JP2025505738A (ja) 2022-02-11 2023-02-10 がんの治療

Country Status (9)

Country Link
US (1) US20250368714A1 (enExample)
EP (1) EP4475955A1 (enExample)
JP (1) JP2025505738A (enExample)
KR (1) KR20240149422A (enExample)
AU (1) AU2023219133A1 (enExample)
CA (1) CA3250299A1 (enExample)
IL (1) IL314687A (enExample)
MX (1) MX2024009818A (enExample)
WO (1) WO2023152335A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229157A1 (en) * 2024-05-01 2025-11-06 Immutep S.A.S. Combination therapy using lag-3 protein and anti-pd-1 inhibitor with radiotherapy for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP4157313A1 (en) * 2020-05-28 2023-04-05 Immutep S.A.S. Treatment of cancer

Also Published As

Publication number Publication date
US20250368714A1 (en) 2025-12-04
MX2024009818A (es) 2024-08-19
IL314687A (en) 2024-10-01
EP4475955A1 (en) 2024-12-18
KR20240149422A (ko) 2024-10-14
CA3250299A1 (en) 2023-08-17
AU2023219133A1 (en) 2024-09-05
WO2023152335A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
KR101894689B1 (ko) 암의 치료 방법
KR102502545B1 (ko) Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
US10744110B2 (en) Methods of treating lung cancer
Chien et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
US20250368714A1 (en) Treatment of cancer
US20240277804A1 (en) Triple combination therapy
Aleksandrovic et al. From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities
Braun et al. Recent advances in cervical cancer treatment
CN118804760A (zh) 癌症的治疗
KR20230028321A (ko) 암의 치료
AU2013203373B2 (en) Methods of treating lung cancer
WO2026039321A1 (en) Methods for treating prostate cancer
Montemurro et al. Selected Highlights from the 26th San Antonio Breast Cancer Symposium
Vasiliou et al. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011-Focus on first-in-human and phase I trials
WARNING PERJETA: for the first-line treatment of HER2+ metastatic breast cancer
HK1220110B (en) Methods of treating lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210